Tumor Microenvironment (TME) Immune Profiling for Live Biotherapeutics

Decoding the Cold TME Bottleneck

Developing live biotherapeutic products for oncology requires moving beyond simple tumor volume measurements. To build a compelling IND-enabling data package, developers must address the profound complexity of the tumor microenvironment.

Immunosuppressive Dominance

Solid tumors frequently recruit Regulatory T cells (Tregs), Myeloid-Derived Suppressor Cells (MDSCs), and M2-polarized macrophages. Demonstrating that an LBP can effectively reverse this suppressive axis requires high-resolution single-cell phenotypic analysis rather than bulk tissue assays.

Tissue Dissociation Artifacts

Extracting viable, representative immune populations from dense solid tumors *ex vivo* is notoriously difficult. Improper enzymatic digestion can cleave critical surface epitopes (e.g., CD4, CD8, immune checkpoints), leading to skewed flow cytometry data and false negatives regarding LBP efficacy.

Mechanistic Ambiguity

Even when tumor regression is observed *in vivo*, attributing the outcome specifically to microbial modulation of host immunity requires correlating shifts in cellular subpopulations with functional cytokine/chemokine gradients within the local TME.

Comprehensive TME Profiling Solutions

We specialize in high-dimensional analytical strategies to map host immune responses triggered by microbial interventions. Our custom and pre-validated panels are optimized for both murine models and humanized xenografts.

1

Lymphoid Infiltration Panels

Quantification of CD8+ cytotoxic T cells, CD4+ helper T cells, and FoxP3+ regulatory T cells. We also incorporate functional markers (e.g., Granzyme B, Ki-67, IFN-γ) and exhaustion markers (PD-1, TIM-3, LAG-3) to determine if your LBP is rescuing exhausted T cells within the TME.

2

Myeloid & Suppressor Cell Panels

Deep phenotyping of the myeloid compartment to track M1 (anti-tumor) vs. M2 (pro-tumor) macrophage polarization (CD11b, F4/80, CD206, MHC-II). We also offer rigorous tracking of monocytic and granulocytic MDSCs (Ly6C/Ly6G) and Dendritic Cell maturation statuses.

3

Multiplex Cytokine Readouts

Profiling of tumor lysates or *in vitro* co-culture supernatants using Luminex or Meso Scale Discovery (MSD) platforms. We quantify critical modulators of the cold-to-hot transition, including IFN-γ, TNF-α, IL-12, IL-10, TGF-β, and key chemokines driving T cell trafficking (CXCL9, CXCL10).

Ready to analyze your TME samples?

Partner with our immunology experts to design a flow cytometry panel tailored to your specific live biotherapeutic strain and target indication.

The Cold-to-Hot Mechanism Scorecard

We track six complementary immunological indicators to generate an integrated, evidence-based scorecard of how your microbial candidate remodels the tumor microenvironment toward a T-cell–inflamed (“hot”) state.

CD8⁺ / Treg Ratio

↑ INCREASE

Tracks the balance of cytotoxic effector T cells versus FoxP3+ regulatory T cells within the tumor.

Measured by: flow cytometry (e.g., CD3, CD8, CD4, FoxP3, CD25; optional Ki-67/Granzyme B).

TAM Repolarization

→ M1 SHIFT

Quantifies macrophage functional repolarization from pro-tumor (M2-like) to inflammatory, antigen-presenting (M1-like) states.

Measured by: flow cytometry (e.g., CD11b, F4/80, CD86, MHC-II, CD206/CD163) and/or cytokine context.

MDSC Burden

↓ REDUCTION

Monitors depletion and/or inhibition of suppressor populations that block T-cell function.

Measured by: flow cytometry (mouse: Ly6G/Ly6C; human: CD11b+CD33+HLA-DRlow/− with PMN- vs M-MDSC stratification).

DC Maturation

↑ ACTIVATION

Assesses antigen-presentation readiness via co-stimulatory upregulation and MHC-II increase on dendritic cells.

Measured by: flow cytometry (e.g., CD11c, MHC-II, CD80, CD86; optional CD103/CD8α subsets).

IFN-γ/Th1 Program

↑ UPREGULATION

Evaluates local Th1-skewed inflammatory signaling required to initiate and sustain effective anti-tumor immunity.

Measured by: multiplex cytokines (IFN-γ, IL-12, TNF-α; optional intracellular IFN-γ in T cells).

CXCL9/10 Trafficking

↑ UPREGULATION

Examines chemokine gradients that support effector T-cell recruitment into the tumor.

Measured by: tumor lysate cytokine/chemokine readouts (e.g., Luminex/MSD) and correlated with T-cell infiltration metrics.

* Directional indicators; interpretation depends on model, timepoint, and dosing regimen.

Actionable Data and Key Deliverables

We output clear, publication-ready datasets and mechanistic interpretations detailing exactly how your microbial candidate reconstructs the tumor immune landscape.

Assay Modality	Target Populations & Markers	Output & Mechanistic Hypothesis Generated
T Cell Activation Panel	CD45, CD3, CD4, CD8, FoxP3, CD25, Ki-67, PD-1	Identifies increases in the CD8+ / Treg ratio; confirms proliferation of cytotoxic effectors in response to LBP administration.
Macrophage Polarization	CD45, CD11b, F4/80, CD86, MHC-II, CD206, CD163	Quantifies the shift from suppressive M2 phenotypes toward inflammatory, antigen-presenting M1 phenotypes.
MDSC Characterization	CD45, CD11b, Ly6C, Ly6G (or human equivalents)	Measures LBP-mediated reduction in myeloid-derived suppressor cell accumulation within the tumor bed.
Soluble Factor Analysis	IFN-γ, TNF-α, IL-10, IL-12p70, TGF-β, IL-6	Maps the local inflammatory cytokine milieu, correlating soluble signals with observed cellular phenotypic shifts.

Published Data: Microbial Modulation of the TME

The strategic use of flow cytometry to profile tumor-infiltrating immune cells is widely recognized as a gold standard for evaluating LBP efficacy. Scientific literature extensively documents how specific microbial strains can systemically alter the immune architecture of solid tumors.

For instance, research evaluating the anti-tumor potential of Bifidobacterium strains often relies on robust TME immune profiling. Published studies have demonstrated that the administration of certain strains, such as B. breve JCM92, can significantly modify the tumor immune microenvironment.

Utilizing multicolor flow cytometry panels, researchers have successfully quantified enhanced recruitment of cytotoxic T cells and corresponding shifts in suppressive cell populations. These measurable immunological alterations are frequently proposed as the underlying mechanism by which these strains synergize with conventional chemotherapeutics (e.g., oxaliplatin) or immune checkpoint inhibitors, effectively establishing an activated, "hot" tumor microenvironment.

B. breve JCM92 increases oxaliplatin response via anti-tumor immune modulation. (Creative Biolabs Authorized)

Fig.1 B. bre JCM92 boosts oxaliplatin efficacy by enhancing anti-tumor immunity.^1,3

Streamlined Workflow for TME Analytics

From robust tissue handling to high-dimensional data analysis, our end-to-end service ensures the preservation of fragile immune populations and the generation of highly reproducible datasets.

1

Panel & Study Design

Collaborative selection of fluorophores and target markers based on the hypothesized mechanism of your specific microbial strain.

2

Model Integration

Seamless execution of in vivo models, or processing of client-provided ex vivo tumor samples under strictly controlled cold-chain conditions.

3

Optimized Dissociation

Application of validated enzymatic and mechanical dissociation protocols that maximize live single-cell yields while protecting sensitive surface epitopes.

4

Flow & Cytokine Assays

High-throughput acquisition using advanced flow cytometers, coupled with multiplexed cytokine quantification from tumor homogenates.

5

Data Interpretation

Advanced gating strategies, statistical analysis, and preparation of comprehensive reports summarizing key immunological shifts.

Integrated Immunology Services for Live Biotherapeutics

TME profiling is a critical piece of the puzzle. Complement your tumor microenvironment studies with our broader suite of immune and cell analytical services to build a holistic, IND-ready data package evaluating the safety, immunogenicity, and targeted efficacy of your microbial candidates.

Immune and Cell Analytics

Comprehensive platforms for evaluating LBP-host cellular interactions.

Flow Cytometry for Probiotic Enumeration

Broad-spectrum flow cytometry applications for immune monitoring.

Synchronized Lysis Circuit Technology

High-sensitivity detection of inflammatory and suppressive mediators.

Immunomodulation Assays for Probiotic MOA

Detailed phenotypic breakdown of systemic immune responses.

LBPs for Cancer Therapeutics

End-to-end preclinical evaluation of oncological microbiome interventions.

Engineered EcN for Cancer Therapy

Targeted drug delivery solutions using engineered E. coli Nissle 1917.

Frequently Asked Questions

While IHC provides excellent spatial context, multicolor flow cytometry allows for high-dimensional, simultaneous analysis of multiple surface and intracellular markers on a single-cell basis. This is crucial for definitively identifying complex functional subsets, such as activated cytotoxic T cells or specific polarization states of macrophages, which is necessary to understand LBP mechanisms.

Enzymatic over-digestion is a common pitfall. We utilize meticulously optimized, tumor-type-specific dissociation protocols. By carefully balancing collagenase/dispase concentrations and incorporating mechanical disruption techniques under controlled temperatures, we maximize cell viability and preserve sensitive epitopes (like CD4 and immune checkpoints) for accurate downstream flow analysis.

Yes. In addition to analyzing serum or plasma, we can process solid tumor tissues into homogenates. Using multiplex immunoassay platforms, we quantify localized concentrations of key chemokines and cytokines within the TME, providing direct evidence of inflammatory shifts triggered by the live biotherapeutic.

Absolutely. While we offer validated standard panels for T cells, B cells, and Myeloid lineages, we routinely collaborate with clients to design bespoke panels. If your microbial strain is hypothesized to affect a specific pathway (e.g., modifying specific DC subsets or upregulating specific exhaustion markers), we will integrate the appropriate fluorophore-conjugated antibodies to test that specific hypothesis.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video

References

Yoon, Youngmin, et al. "Bifidobacterium strain-specific enhances the efficacy of cancer therapeutics in tumor-bearing mice." Cancers 13.5 (2021): 957. https://doi.org/10.3390/cancers13050957
Manole, Simin, et al. "Setting “cold” tumors on fire: Cancer therapy with live tumor-targeting bacteria." Med 6.1 (2025). https://doi.org/10.1016/j.medj.2024.11.002
Distributed under Open Access license CC BY 4.0, without modification.